CNS MCL relapse characteristics
| . | Ibrutinib Cohort (n = 29), n (%) . | BBB Cohort (n = 29), n (%) . | Other Therapy Cohort (n = 30), n (%) . | Total (n = 88), n (%) . |
|---|---|---|---|---|
| Patient characteristics | ||||
| Age (yr), median (range) | 67 (48-82) | 60 (39-87) | 70 (43-80) | 65 (39-87) |
| Disease characteristics | ||||
| Time to CNS relapse, mo (range) | 24 (1-85) | 13 (3-99) | 18 (2-122) | 16 (1-122) |
| CNS POD ≤24 mo | 14/29 (48) | 20/29 (69) | 18/30 (60) | 52/88 (59) |
| Extra CNS involvement | 10/29 (35) | 9/17 (53) | 9/19 (47) | 28/65 (43) |
| CNS involvement pattern | ||||
| Leptomeningeal | 13/29 (45) | 14/24 (58) | 13/25 (52) | 40/78 (51) |
| Parenchymal | 10/29 (34) | 2/24 (9) | 6/25 (24) | 18/78 (23) |
| Both | 6/29 (21) | 8/24 (33) | 6/25 (24) | 20/78 (26) |
| CNS MCL therapy | ||||
| Ibrutinib | 29/29 (100) | — | — | 29/88 (33) |
| HD-MTX | — | 7/29 (24) | — | 7/88 (8) |
| HD-MTX-ARAC | — | 20/29 (69) | — | 20/88 (23) |
| HD-IFO | — | 2/29 (7) | — | 2/88 (2) |
| IT therapy | — | — | 17/30 (57) | 17/88 (19) |
| Bendamustine-based regimen | — | — | 6/30 (20) | 6/88 (7) |
| Palliation | — | — | 7/30 (23) | 7/88 (8) |
| Additional CNS MCL therapies | ||||
| IT therapy | 12/29 (41) | 23/29 (79) | 5/30 (17) | 40/88 (46) |
| Rituximab | 4/29 (14) | 10/28 (36) | 7/27 (26) | 21/84 (25) |
| Consolidative RT | 1/26 (4) | 2/17 (12) | 7/18 (39) | 10/61 (16) |
| Number of prior therapies before CNS relapse | 1 (1-2) | 1 (1-5) | 1 (1-3) | 1 (1-5) |
| . | Ibrutinib Cohort (n = 29), n (%) . | BBB Cohort (n = 29), n (%) . | Other Therapy Cohort (n = 30), n (%) . | Total (n = 88), n (%) . |
|---|---|---|---|---|
| Patient characteristics | ||||
| Age (yr), median (range) | 67 (48-82) | 60 (39-87) | 70 (43-80) | 65 (39-87) |
| Disease characteristics | ||||
| Time to CNS relapse, mo (range) | 24 (1-85) | 13 (3-99) | 18 (2-122) | 16 (1-122) |
| CNS POD ≤24 mo | 14/29 (48) | 20/29 (69) | 18/30 (60) | 52/88 (59) |
| Extra CNS involvement | 10/29 (35) | 9/17 (53) | 9/19 (47) | 28/65 (43) |
| CNS involvement pattern | ||||
| Leptomeningeal | 13/29 (45) | 14/24 (58) | 13/25 (52) | 40/78 (51) |
| Parenchymal | 10/29 (34) | 2/24 (9) | 6/25 (24) | 18/78 (23) |
| Both | 6/29 (21) | 8/24 (33) | 6/25 (24) | 20/78 (26) |
| CNS MCL therapy | ||||
| Ibrutinib | 29/29 (100) | — | — | 29/88 (33) |
| HD-MTX | — | 7/29 (24) | — | 7/88 (8) |
| HD-MTX-ARAC | — | 20/29 (69) | — | 20/88 (23) |
| HD-IFO | — | 2/29 (7) | — | 2/88 (2) |
| IT therapy | — | — | 17/30 (57) | 17/88 (19) |
| Bendamustine-based regimen | — | — | 6/30 (20) | 6/88 (7) |
| Palliation | — | — | 7/30 (23) | 7/88 (8) |
| Additional CNS MCL therapies | ||||
| IT therapy | 12/29 (41) | 23/29 (79) | 5/30 (17) | 40/88 (46) |
| Rituximab | 4/29 (14) | 10/28 (36) | 7/27 (26) | 21/84 (25) |
| Consolidative RT | 1/26 (4) | 2/17 (12) | 7/18 (39) | 10/61 (16) |
| Number of prior therapies before CNS relapse | 1 (1-2) | 1 (1-5) | 1 (1-3) | 1 (1-5) |
HD-ARA-C, high dose of cytosine arabinoside; HD-IFO, high dose ifosfamide; HD-MTX, high dose methotrexate; Other therapy cohort, nonpenetrating blood brain barrier therapy cohort; RT, radiotherapy.